{'fraction_non_alphanumeric': 0.02413793103448276, 'fraction_numerical': 0.006896551724137931, 'mean_word_length': 5.046875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Some newer approaches to the treatment of the mucosa of patients with superficial bladder cancer: 1. Continuous bladder irrigation with 5-fluorouracil.

One of the most challenging problems in urology is the management of the patient with superficial bladder cancer (stage 0, A or Ti). The tumours are often readily destroyed by simple means and, provided they are well differentiated, there is little likelihood of dissemination. However, the prognosis in such a patient is dependent on the malignant potential of the bladder mucosa remaining after the ablation of the presenting tumour. The bladder is a reservoir, and the carcinogens responsible for the initiation of bladder cancer are probably excreted in the urine. Because the entire bladder mucosa is exposed to these carcinogens the mucosal abnormalities can be widespread. However, they may not be grossly visible. Many of the "recurrences" (really new tumours occurring at new sites) originate in these areas of epithelial dysplasia. The problem of recurrences in patients with superficial bladder cancer is serious. In one series1 the recurrence rate was 73%. Approximately 20% of the recurrent tu-